Member Info for Babbler2

Some posters here this morning obviously weren't expecting and RNS and wanted more time to buy back in. IMO.

Excellent news for patients... might not quite go majorly up as its 2020 timeline... One to build until then imo.

Could it be that Align are being cautious as it affects their position in the share... who knows but they seem to agree 0.4p is floor and 0.4-0.5 buying is good value.

Time will tell...

Babblers Best Bets? @BabblerBestBets · 13m13 minutes ago

? More


Good Morning all. Papers out:
TOM placing @ 2.75p - been ramped lately?
MTFB granted FDA meeting - 3rd May key date for diaries!
DNL one to keep an eye on
BLOE Significant oil and gas shows
BCN TR-1 sellers RNS
UJO Placing

Will be watching closely. Delayed trades as expected reported.

The shares are not without risk and the unique financing structure provides opportunity for nimble traders. Our stance is that as the stock approaches the floor of the 15 day 90% VWAP conversion price (see piece HERE ref how this works) there is an attractive risk/reward profile (currently around 0.37p based on the present 15 day count). Vice versa on runs towards 1p then it is appropriate to book profits.

For now however, given the continued high interest in the stock we note that applying 50% of the UNILAD administration sale valuation to WideCells (not an unreasonable ballpark valuation in our view) implies a market cap of c.£8.5 million. We value the legacy WideCells stem cell research business at zero such is our view of incumbent subsidiary management headed by Joao Andrade. On a worst case expanded share count this equates to 0.57p per share. Should the expanded final count be around 850 million if the stock remains between 0.4 & 0.5p then we arrive at a stock price of c.1p.

DS Quote: "Both the Board and the team are committed to achieving net positive free cashflow this year. “

"The initial 6-12 months will see the launch of the Agency Consultancy division. This business is seen as being quickly scalable and will drive early, high-margin, recurring revenues. At the same time, the distribution and publishing division will be built through organic and inorganic growth. The Content Licensing and E-Commerce divisions will then be launched, followed by the video production division. "

Research piece is out:

http://www.alignresearch.co.uk/widecells/widecells-unveils-new-corporate-strategy/

ps... that was said tongue in cheek BTW... I'm sure you all have...

Morning.... I've found their new website... anyone else looked?

https://www.iconiclabs.co.uk

if you are thinking about todays trading on the RNS - couldn't buy easily until .44.. I tried!

You do realise some cant be converted until after June right?

Align tweet:

Full blog update to come tomorrow on new Widecells #WDC business direction.

MCAP Now £2.877m with the new shares issued.

Yup. Easy money for researched amongst us.

Sellers - never mind... there will probably be another chance ;)

Lovely... time for another bounce to 0.55+

couldn't buy at 0,83 so left it. GL.